

29 November 2013

TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2011/12 Invitation to Tender, dated 1 November 2011 and the 2012/13 Invitation to Tender, dated 31 October 2012.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2011/12 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2015

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Methotrexate	tab 2.5 mg; 30 tablet blister pack ¹ .	\$5.22	\$3.82	Trexate (Rex Medical Ltd)	1 April 2014	1 June 2014	1 September 2014	Methoblastin (Pfizer)
Methotrexate	tab 10 mg; 50 tablet blister pack ¹ .	\$40.93	\$26.25	Trexate (Rex Medical Ltd)	1 April 2014	1 June 2014	1 September 2014	Methoblastin (Pfizer)

¹A Brand Switch Fee of \$4.33 is payable for this product from 1 September 2014 until 1 December 2014

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Methotrexate	tab 2.5 mg; 30 tablet blister pack	\$5.22	\$3.82	Trexate (Rex Medical)	1%	1 April 2014	1 June 2014	Methoblastin (Pfizer)
Methotrexate	tab 10 mg; 50 tablet blister pack	\$40.93	\$26.25	Trexate (Rex Medical)	1%	1 April 2014	1 June 2014	Methoblastin (Pfizer)

2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Dexamethasone phosphate	inj 4 mg per ml, 1 ml ampoule; 10 ampoules	\$21.50 (per 5 ampoules)	\$25.80 (per 10 ampoules)	Dexamethasone- hameln (Max Health)	1 February 2014	1 April 2014	1 July 2014	Hospira (Hospira)
Dexamethasone phosphate	inj 4 mg per ml, 2 ml ampoule; 5 ampoules	\$31.00	\$17.98	Dexamethasone- hameln (Max Health)	1 February 2014	1 April 2014	1 July 2014	Hospira (Hospira)

3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Ibuprofen	oral liq 20 mg per ml; 200 ml bottle	\$2.69	\$1.89	Fenpaed (AFT)	1 January 2014	1 April 2014

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Dexamethasone phosphate	inj 4 mg per ml, 1 ml ampoule; 10 ampoules	\$21.50 (per 5 ampoules)	\$25.80 (per 10 ampoules)	Dexamethasone-hameln (Max Health)	1%	1 February 2014	1 April 2014	Hospira (Hospira)
Dexamethasone phosphate	inj 4 mg per ml, 2 ml ampoule; 5 ampoules	\$31.00	\$17.98	Dexamethasone-hameln (Max Health)	1%	1 February 2014	1 April 2014	Hospira (Hospira)

5. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Ibuprofen	oral liq 20 mg per ml; 200 ml bottle	\$2.69	\$1.89	Fenpaed (AFT)	1%	1 January 2014	1 April 2014

For products included in the 2011/12 Invitation to Tender or the 2012/13 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.